IL315011A - Dosing regimens for suppression of cytokine release syndrome using odronuxtamb - Google Patents

Dosing regimens for suppression of cytokine release syndrome using odronuxtamb

Info

Publication number
IL315011A
IL315011A IL315011A IL31501124A IL315011A IL 315011 A IL315011 A IL 315011A IL 315011 A IL315011 A IL 315011A IL 31501124 A IL31501124 A IL 31501124A IL 315011 A IL315011 A IL 315011A
Authority
IL
Israel
Prior art keywords
odronextamab
mitigation
cytokine release
dosing regimens
release syndrome
Prior art date
Application number
IL315011A
Other languages
English (en)
Hebrew (he)
Inventor
Srikanth R Ambati
Aafia Chaudhry
Hesham Mohamed
Toroghi Masood Khaksar
Min Zhu
Original Assignee
Regeneron Pharma
Srikanth R Ambati
Aafia Chaudhry
Hesham Mohamed
Toroghi Masood Khaksar
Min Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Srikanth R Ambati, Aafia Chaudhry, Hesham Mohamed, Toroghi Masood Khaksar, Min Zhu filed Critical Regeneron Pharma
Publication of IL315011A publication Critical patent/IL315011A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL315011A 2022-02-25 2023-02-24 Dosing regimens for suppression of cytokine release syndrome using odronuxtamb IL315011A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263313932P 2022-02-25 2022-02-25
US202263393212P 2022-07-28 2022-07-28
US202263420782P 2022-10-31 2022-10-31
US202263424210P 2022-11-10 2022-11-10
US202363440304P 2023-01-20 2023-01-20
PCT/US2023/013836 WO2023164143A1 (en) 2022-02-25 2023-02-24 Dosing regimens for mitigation of cytokine release syndrome with odronextamab

Publications (1)

Publication Number Publication Date
IL315011A true IL315011A (en) 2024-10-01

Family

ID=85778997

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315011A IL315011A (en) 2022-02-25 2023-02-24 Dosing regimens for suppression of cytokine release syndrome using odronuxtamb

Country Status (11)

Country Link
US (1) US20230272118A1 (https=)
EP (1) EP4482524A1 (https=)
JP (1) JP2025508832A (https=)
KR (1) KR20240167457A (https=)
CN (1) CN119156226A (https=)
AU (1) AU2023224098A1 (https=)
CA (1) CA3244791A1 (https=)
IL (1) IL315011A (https=)
MX (1) MX2024010292A (https=)
TW (1) TW202400228A (https=)
WO (1) WO2023164143A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA3110513A1 (en) * 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
TW202135860A (zh) 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物

Also Published As

Publication number Publication date
AU2023224098A1 (en) 2024-09-12
MX2024010292A (es) 2024-12-06
US20230272118A1 (en) 2023-08-31
WO2023164143A1 (en) 2023-08-31
CN119156226A (zh) 2024-12-17
JP2025508832A (ja) 2025-04-10
TW202400228A (zh) 2024-01-01
EP4482524A1 (en) 2025-01-01
KR20240167457A (ko) 2024-11-26
CA3244791A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
EP3802578A4 (en) SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY
CA201258S (en) Cradle for leg support
ZA201700211B (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
IL289949A (en) Dosing regimens for oral complement factor d inhibitors
IL291453A (en) Dosage forms for tyk2 inhibitors
IL288517A (en) Closed system drug delivery devices for solid dosage forms
IL308389A (en) Dosing regimens for acubactadine
PL4025187T3 (pl) Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu
LT4025188T (lt) Dozavimo režimai susiję su prailginto atpalaidavimo paliperidono injekcinėmis vaisto formomis
IL304502A (en) Compositions and methods for treating cytokine release syndrome
LT4025189T (lt) Dozavimo režimai, susiję su prailginto atpalaidavimo paliperidono palmitato injekcinėmis vaisto formomis
IL288210B2 (en) Dosing regimens of IL-2/IL-15 beta-gamma receptor agonists for the treatment of cancer or infectious diseases
SG11202101574PA (en) Ue indication of supported number of trigger states
IL315886A (en) Dosing regimens for anti-CD19 agents and their uses
IL315011A (en) Dosing regimens for suppression of cytokine release syndrome using odronuxtamb
HK40121121A (en) Dosing regimens for mitigation of cytokine release syndrome with odronextamab
IL279214A (en) Therapeutic dosage regimens comprising adherent stromal cells
IL325764A (en) Designed compositions of interleukin-2 cytokine and methods of use
IL308095A (en) Dosing regimens
IL315178A (en) Dosage regimen
ZA202210315B (en) Peptide for the treatment of cytokine storm syndrome
GB202108834D0 (en) Component for use with non-combustible aerosol provision device
GB2613487B (en) Methods and compositions for treating cytokine release syndrome
GB202510805D0 (en) Dosing regimens for orellanine
GB202308365D0 (en) Semaglutide dosing